share_log

SAGALIAM ACQUISITION CORP. ANNOUNCES EXECUTION OF DEFINITIVE BUSINESS COMBINATION AGREEMENT AND RECEIPT OF NASDAQ LISTING DELINQUENCY LETTER

SAGALIAM ACQUISITION CORP. ANNOUNCES EXECUTION OF DEFINITIVE BUSINESS COMBINATION AGREEMENT AND RECEIPT OF NASDAQ LISTING DELINQUENCY LETTER

SAGALIAM 收購公司宣佈執行最終業務合併協議並收到納斯達克上市違約信
GlobeNewswire ·  2023/09/16 04:47

New York, NY, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Sagaliam Acquisition Corp. (NASDAQ: "SAGAU", "SAGA", "SAGAR") ("we", "us", "our", or the "Company") announced today that it received a delinquency notification letter ("Notice") from the Listing Qualifications staff of the Nasdaq Stock Market LLC ("Nasdaq") on July 25, 2023 due to the Company's non-compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company's failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2023 (the "Form 10-K"). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC").

紐約,紐約州,9月環球通訊社2023年3月15日--薩加裡姆收購公司(納斯達克:“SAGAU”,“SAGA”,“SAGA”)(“我們“,”我們“,”我們的,或“公司Y“)今天宣佈收到一封拖欠通知書(”告示“)來自納斯達克上市資格的工作人員(”納斯達克“)於2023年7月25日,因本公司未能及時提交其截至2023年3月31日的10-Q表格季度報告而違反納斯達克上市規則第5250(C)(1)條(”表格10-K“)。納斯達克上市規則第5250(C)(1)條要求上市公司及時向美國證券交易委員會提交所有規定的定期財務報告。美國證券交易委員會“)。

The Notice states that the Company has until September 25, 2023 to submit to Nasdaq a plan to regain compliance with the Nasdaq Listing Rules. If Nasdaq accepts the Company's plan, then Nasdaq may grant the Company up to 180 calendar days from the prescribed due date for filing the Form 10-Q or until November 20, 2023 to regain compliance. If Nasdaq does not accept the Company's plan, then the Company will have the opportunity to appeal that decision to a Nasdaq Hearings Panel.

通知指出,本公司須於2023年9月25日前向納斯達克提交重新遵守納斯達克上市規則的計劃。如果納斯達克接受公司的計劃,納斯達克可以允許公司在提交10-Q表格的規定截止日期起180個日曆日內,或到2023年11月20日之前重新獲得合規。如果納斯達克不接受公司的計劃,公司將有機會向納斯達克聽證會小組提出上訴。

As previously disclosed, the Company requires additional time to prepare, review and finalize its financial statements, and its auditors have not completed their audit of the financial statements. The Company is continuing in its efforts to file the Form 10-Q as soon as reasonably practicable.

正如以前披露的那樣,該公司需要額外的時間來編制、審查和最後確定其財務報表,而其審計員尚未完成對財務報表的審計。該公司正繼續努力在合理可行的情況下儘快提交10-Q表格。

The Company has executed a binding business combination agreement for the purchase of Biogenysis, Inc. ("BGEN") and Virogentics Inc. ("VIRO"), operating subsidiaries of Enzolytics Inc. (OTC PK: ENZC). The combined company is expected to trade on NASDAQ.

該公司已經簽署了一項具有約束力的業務合併協定,收購Enzolytics公司(場外交易代碼:ENZC)的運營子公司生物遺傳公司(“Bgen”)和病毒學公司(“Viro”)。合併後的公司預計將在納斯達克上市。

This announcement is made in compliance with Nasdaq Listing Rule 5250(b)(2).

本公告乃根據納斯達克上市規則第5250(B)(2)條作出。

About Enzolytics

關於Enzolytics

Enzolytics, Inc. is a drug development company committed to commercializing its proprietary proteins and monoclonal antibodies to treat debilitating infectious diseases. The Company is advancing multiple therapeutics targeting numerous infectious diseases. One patented and clinically tested compound, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin Fraction (IPF), covered by U.S. Patent Nos. 8,066,982 and 7,479,538. Studies have shown it to be effective in treating HIV/AIDS. ITV-1 has also been shown to modulate the immune system.

Enzolytics公司是一家藥物開發公司,致力於將其專利蛋白質和單抗商業化,以治療令人衰弱的傳染病。該公司正在推進針對多種傳染病的多種療法。一種獲得專利並經過臨床測試的化合物ITV-1(免疫治療疫苗-1)是滅活胃蛋白酵部分(IPF)的懸浮劑,美國專利號為8,066,982和7,479,538。研究表明,它在治療愛滋病毒/艾滋病方面有效。ITV-1也被證明可以調節免疫系統。

The Company has proprietary technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases which is currently being employed to produce monoclonal antibody therapeutics for treating the CoronaVirus (SARS-CoV-2), HIV-1 and the Feline Leukemia virus. The Company has also identified conserved epitopes on and has plans to produce mAbs targeting many other viruses, including HIV-2, Influenza A and B, H1N1 influenza, Respiratory syncytial virus (RSV), Small-Pox, Ebola Virus, Tetanus, Diphtheria, HTLV-1/2, Rabies, Herpes zoster, Varicella zoster, Anthrax, Mason-Pfizer monkey virus (MPMV) and Visna virus (VISNA). The Company has also analyzed epitopes of animal viruses and plans to produce mAbs for treating these animal viruses.

該公司擁有生產針對傳染病的全人類單抗的專利技術,目前正被用於生產治療冠狀病毒(SARS-CoV-2)、愛滋病毒-1和貓白血病病毒的單抗療法。該公司還確定了許多其他病毒的保守表位,並計劃生產針對許多其他病毒的單抗,包括愛滋病毒-2、甲型和乙型流感、H1N1流感、呼吸道合胞病毒(RSV)、小痘、埃博拉病毒、破傷風、白喉、HTLV-1/2、狂犬病、帶狀皰疹、水痘帶狀皰疹、炭疽、梅森-輝瑞猴子病毒(MPMV)和Visna病毒(Visna)。該公司還分析了動物病毒的表位,並計劃生產用於治療這些動物病毒的單抗。

About Sagaliam Acquisition Corp.

關於Sagaliam收購公司

We are a blank check company incorporated under the laws of the State of Delaware on March 31, 2021 for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or entities. Sagaliam intends to continue to pursue the consummation of a business combination with an appropriate target.

我們是一家空白支票公司,於2021年3月31日根據特拉華州法律成立,目的是與一個或多個企業或實體進行合併、資本股票交換、資產收購、股票購買、重組或類似的業務合併。Sagaliam打算繼續追求與適當目標的業務合併的完善。

Forward Looking Statements

前瞻性陳述

The disclosure herein includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook," and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations, Company's ability to enter into a definitive business combination agreement and Company's ability to obtain the financing necessary to consummate the potential business combination transaction. These statements are based on various assumptions and on the current expectations of Company's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Company. These forward-looking statements are subject to a number of risks and uncertainties, including: Company's ability to enter into a definitive agreement with respect to the proposed business combination or consummate a transaction; the risk that the approval of the stockholders of Company for the potential transaction is not obtained; failure to realize the anticipated benefits of the potential transaction, including as a result of a delay in consummating the potential transaction or difficulty in integrating the businesses of Company; the amount of redemption requests made by Company's stockholders and the amount of funds remaining in Company's trust account after satisfaction of such requests; those factors discussed in Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022 under the heading "Risk Factors," and other documents of Company filed, or to be filed, with the SEC. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Company presently does not know or that Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Company's expectations, plans or forecasts of future events and views as of the date hereof. Company anticipates that subsequent events and developments will cause Company's assessments to change. However, while Company may elect to update these forward-looking statements at some point in the future, Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Company's assessments as of any date subsequent to the date of this disclosure statement. Accordingly, undue reliance should not be placed upon the forward-looking statements.

本文中披露的某些陳述不是歷史事實,但為了1995年美國私人證券訴訟改革法下的安全港條款的目的,這些陳述是前瞻性陳述。前瞻性陳述通常伴隨著諸如“相信”、“可能”、“將”、“估計”、“繼續”、“預期”、“打算”、“預期”、“應該”、“將”、“計劃”、“預測”、“潛在”、“似乎”、“尋求”、“未來”、“展望”等詞語,以及預測或表明未來事件或趨勢的類似表達,或者不是歷史事件或趨勢的陳述。這些前瞻性陳述包括但不限於對收入和其他財務和業績指標的預測、估計和預測,以及對市場機會和預期的預測,公司簽訂最終業務合併協定的能力,以及公司獲得完成潛在業務合併交易所需融資的能力。這些陳述是基於各種假設和對公司管理層目前的預期,並不是對實際業績的預測。這些前瞻性陳述僅用於說明目的,並不打算用作任何投資者的擔保、保證、預測或對事實或可能性的明確陳述,也不得將其作為任何投資者的依賴。實際事件和情況很難或不可能預測,並將與假設有所不同。許多實際事件和情況都超出了公司的控制範圍。這些前瞻性陳述受一系列風險和不確定因素的影響,包括:公司就擬議的業務合併或完成交易達成最終協定的能力;未獲得公司股東對潛在交易的批准的風險;未能實現潛在交易的預期收益,包括延遲完成潛在交易或整合公司業務的困難;公司股東提出的贖回請求的金額以及滿足這些要求後公司信託賬戶中剩餘的資金金額;公司在截至2022年12月31日的財政年度的Form 10-K年度報告中“風險因素”標題下討論的因素,以及公司已提交或將提交給美國證券交易委員會的其他檔案中討論的那些因素。如果風險成為現實或假設被證明是不正確的,實際結果可能與這些前瞻性陳述所暗示的結果大不相同。可能存在公司目前不知道或公司目前認為不重要的其他風險,這些風險也可能導致實際結果與前瞻性陳述中包含的結果不同。此外,前瞻性陳述反映了公司對未來事件的預期、計劃或預測,以及截至本文發佈之日的看法。公司預計後續事件和發展將導致公司的評估發生變化。然而,雖然公司可能會選擇在未來某個時候更新這些前瞻性陳述,但公司明確表示不承擔任何這樣做的義務。這些前瞻性陳述不應被視為代表公司在本披露陳述日期之後的任何日期的評估。因此,不應過分依賴前瞻性陳述。

CONTACT INFORMATION

聯繫資訊

Sagaliam Acquisition Corp.,
Barry Kostiner, Chief Executive Officer
1800 Avenue of the Stars, Suite 1475
Los Angeles, CA 90067
Tel: (213) 616-0011
bkostiner@fintecham.com

Sagaliam收購公司,
首席執行官巴裡·科斯特納
星光大道1800號,套房1475
加利福尼亞州洛杉磯,郵編:90067
電話:(213)616-0011
郵箱:bkostiner@fintecham.com


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論